Nirmit Kumar, Senior Global Medical Strategy Leader at AstraZeneca, shared a post on X:
“Excellent debate on the benefit of chemo in premenopausal patients with Recurrence Score (RS) ≤ 25 between Sara Tolaney and Kevin Kalinsky.
Tolerability of ovarian function suppression varies so adjuvant chemotherapy usually recommended depending on patient’s clinical profile.”
